Kenneth Fong

Takara Bio USA, Inc. helps to accelerate the discovery process by providing pioneering tools that enable researchers to ask new questions and investigate ever more complex systems than was previously possible. With more than 5,000 literature citations, its innovative products and services continue to facilitate advancement in areas such as genomics, cancer research, apoptosis, cytogenetics, developmental genetics, cellular physiology, pharmocogenetics, and neurobiology.

Vivo Capital LLC (Vivo Capital) is a venture capital firm founded in 1996 by Frank C. Kung and Edgar G. Engleman. The firm is headquartered in Palo Alto, California.

Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.

Kenson Ventures LLC (Kenson Ventures) is a venture capital firm founded in 1999 by Kenneth Fong. The firm is headquartered in in Palo Alto, California.

Committee of 100 provides grant making services. The non-profit company is based in New York, NY. The company was founded in 1988 by Henry Alfred Kissinger, Ieoh Ming Pei.

System Biosciences LLC develops proprietary siRNA and microRNA technologies. Its products include lentiviral technology, genome engineering, molecular tools, stem cell research, exosome research, microrna research and immunology. The company was founded by Kenneth Fong in July 2002 and is headquartered in Palo Alto, CA.

DiagCor Bioscience, Inc. Ltd. develops and commercializes in vitro diagnostic kits and instruments. It offers a complete platform for commercial and clinical MDx diagnosis. The firm serves clinical diagnostic services markets in Latin America, Europe, Middle East and South East Asia. Its products include R2-M flow-through hybridization system, FT-PRO flow-through hybridization system, capture-PRO image capture system, Taigen VacEZor and FT-PRO auto system. The company was founded by Joseph Wing On Tam in 2006 and is headquartered in Hong Kong.